Open AccessBody Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Author(s) -
Tim A. Labeur,
Jeroen L.A. van Vugt,
David W. G. ten Cate,
R. Bart Takkenberg,
Jan N.M. IJzermans,
Bas Groot Koerkamp,
Robert A. de Man,
Otto M. van Delden,
Ferry A.L.M. Eskens,
HeinzJosef Klümpen
Publication year - 2018
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000493586
Subject(s) - sorafenib , hepatocellular carcinoma , medicine , gastroenterology , retrospective cohort study , body mass index , toxicity , adipose tissue , cohort , oncology
Previous studies have suggested body composition as a predictor of sorafenib toxicity and outcome in patients with advanced hepatocellular carcinoma (HCC). Large studies on the impact of body composition parameters in European HCC patients are lacking. Our aim was to validate the prognostic value of body composition parameters in Dutch patients with HCC treated with sorafenib.